Therapeutic Innovation

Therapeutic Innovation

Would it surprise you to know that we bring innovation to the field of generic medicine? Or that our worldwide research and development group includes more than 3,000 scientists?

The Science of Solutions

Today we manufacture bioequivalent versions of brand name medicines, many of which are difficult-to-manufacture and difficult-to-formulate. We strive to create enhanced versions of medicines to differentiate our products. We pursue innovations in oral solid dose medicines, transdermals, injectables, creams and ointments.

Why? Because we believe every disease can have a treatment. We believe every epidemic should come to an end. Medical conditions great and small should be manageable.

  • Allergy Drugs


    Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every minute matters and immediate access to emergency medical care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment, because even one anaphylactic episode without access to emergency treatment, is one too many.

  • Antiretroviral Drugs

    Antiretrovirals (ARV)

    Often, treatment regimens require a patient to take three or more medicines and may include an ARV medicine that breaks down if not refrigerated. Many places hardest hit by the epidemic are in warm climates—Africa and India, for instance—where refrigeration can be scarce. For such regions, Mylan was able to make a heat-stable version of an ARV medicine that doesn’t require refrigeration.

  • Cardiovascular Drugs


    Our commitment to cardiovascular medicine beats strongly. Using our transdermal technology we have formulated adhesive patches that deliver medicine through the skin.

  • Respiratory Drugs


    We’re developing asthma and chronic obstructive pulmonary disease (COPD) treatments that use a dry-powder drug-delivery platform technology. 
  • Skin Creams


    While we manufacture products in many formats—from tablets and capsules to injectables and transdermals—we also produce creams and ointments for dermatology. Our commitment to these medicines gained strength during the 1990s, when we acquired Bertek Pharmaceuticals. Today, we have several products in clinical trials awaiting approval as well as many creams, ointments, sprays and dressings.

  • CNS Drugs

    Central Nervous System

    In the U.S., Mylan products are the second-most dispensed in the neurologic category. These are difficult-to-manufacture and difficult-to-formulate products that treat serious diseases.

Always Moving Forward

Innovation is a part of who we are and the reason we see the opportunity in every challenge.

Research and development

Last Updated  30/10/2018